Sars-COV-2 therapeutic AZD7442

Ended Definitive Contract Awarded Last action

Contract number
W911QY20C0119
Awardee
Awarding agency
Obligated
$1,107,934,203

Award facts

Contract value 100% obligated
$1,107,934,203.08 Current and potential, with all options
Completion date 100% complete
  • Current, with exercised options
  • Potential, with all options
Funding agency
Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
Set-aside
No set-aside
Competition
Full and Open Competition · 6 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
South Korea

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00010 · Covid 19 action. / pre-exposure prophylactic AZD -$33,797
Supplemental Agreement for work within scope P00009 · Sars-COV-2 pre-exposure prophylactic AZD $0
Other Administrative Action P00008 · The purpose of this modification is to update the government technical points of contact and contracting officer $0
Supplemental Agreement for work within scope P00007 · Sars-COV-2 pre-exposure prophylactic AZD modification to change distribution. $1,132,000
Change Order P00006 · The purpose of this modification is to up the point of acceptance for 50K doses. $0
Additional Work (new agreement, FAR part 6 applies) P00005 · DOD and HHS, in support of the national emergency response to covid-19, requires the manufacture, distribution and storage of up to 1M doses of astrazeneca… $855,000,000
Supplemental Agreement for work within scope P00004 $6,870,000
Supplemental Agreement for work within scope P00003 $0
Other Administrative Action P00002 $0
Supplemental Agreement for work within scope P00001 · Sars-COV-2 therapeutic AZD7442 additional doses $204,880,000
Definitize Letter Contract PZ0001 $10,086,000
Original award $30,000,000
Show all 12

About this award

Written by GovTribe AI ·

The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a definitive contract valued at approximately $1.1 billion to Astrazeneca Pharmaceuticals LP. The firm fixed price contract is to provide SARS-COV-2 THERAPEUTIC AZD7442 to the Department of Defense from September 2020 through September 2023. The work will be performed in South Korea. Astrazeneca Pharmaceuticals LP is the prime contractor on this contract to deliver a COVID-19 therapeutic to the Department of the Army under its chemical and biological defense programs. No major subcontractors or set aside designations were indicated.

Quick answers

Who was awarded contract W911QY20C0119?

W911QY20C0119 was awarded to Astrazeneca Pharmaceuticals LP by ACC Aberdeen Proving Ground (Army Contracting Command) on September 30, 2020.

How much is contract W911QY20C0119 worth?

The government has obligated $1,107,934,203 on W911QY20C0119.

Which agency awarded contract W911QY20C0119?

ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911QY20C0119, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).

Was contract W911QY20C0119 competed?

The extent of competition for W911QY20C0119 was full and open competition. The government received 6 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login